Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$1.5 million.

  • Inhibrx Biosciences' Change in Account Payables fell 23755.56% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.6 million, marking a year-over-year decrease of 12336.2%. This contributed to the annual value of $17.9 million for FY2024, which is 74888.57% up from last year.
  • As of Q3 2025, Inhibrx Biosciences' Change in Account Payables stood at -$1.5 million, which was down 23755.56% from -$600000.0 recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year Change in Account Payables high stood at $17.4 million for Q2 2024, and its period low was -$3.1 million during Q4 2024.
  • Over the past 3 years, Inhibrx Biosciences' median Change in Account Payables value was -$450000.0 (recorded in 2024), while the average stood at $1.9 million.
  • In the last 5 years, Inhibrx Biosciences' Change in Account Payables soared by 7175.14% in 2024 and then plummeted by 23755.56% in 2025.
  • Inhibrx Biosciences' Change in Account Payables (Quarter) stood at $2.9 million in 2023, then tumbled by 207.18% to -$3.1 million in 2024, then surged by 51.3% to -$1.5 million in 2025.
  • Its Change in Account Payables was -$1.5 million in Q3 2025, compared to -$600000.0 in Q2 2025 and -$353000.0 in Q1 2025.